During the last session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s traded shares were 1.35 million, with the beta value of the company hitting 0.37. At the end of the trading day, the stock’s price was $0.36, reflecting an intraday loss of -7.87% or -$0.03. The 52-week high for the BCLI share is $2.21, that puts it down -513.89 from that peak though still a striking 63.89% gain since the share price plummeted to a 52-week low of $0.13. The company’s market capitalization is $25.26M, and the average trade volume was 804.42K shares over the past three months.
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information
Brainstorm Cell Therapeutics, Inc. (BCLI) registered a -7.87% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -7.87% in intraday trading to $0.36, hitting a weekly high. The stock’s 5-day price performance is -6.75%, and it has moved by -30.28% in 30 days. Based on these gigs, the overall price performance for the year is -83.24%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts
Statistics show that Brainstorm Cell Therapeutics, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Brainstorm Cell Therapeutics, Inc. (BCLI) shares have gone up 56.70% during the last six months, with a year-to-date growth rate more than the industry average at 45.10% against 15.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.57%. While earnings are projected to return 67.50% in 2024.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc. is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
